82.4% of patients without prior CAR-T achieving Complete Response (CR) or better

ROCKVILLE, Md. and SUZHOU, China, Sept. 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, and IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced updated long-term follow-up data from two studies for BMCA CAR-T: (1) Results from phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel (Abstract Code P-290) and (2) A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T Treatment (Abstract Code P-288) at the 2023 International Myeloma Society (IMS) Annual Meeting in Vienna on September 27-30, 2023.

Poster Presentation #1 Overview

Presentation Title: Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel

Session Title: Treatment of Relapsed/Refractory Multiple Myeloma

Abstract Code: P-290

Session Date and Time: Saturday, September 28, 2023, 12:30 PM - 1:30 PM EEST

Equecabtagene Autoleucel is a chimeric antigen receptor T-cell (CAR-T) therapy featuring fully human B-cell maturation antigen (BCMA)-targeting single-chain fragment variable (scFv) antibody. The updated data showed long-term follow-up efficacy, safety, and persistence of the phase 1b/2 study (FUMANBA-1) conducted in 14 clinical sites in China.

This study enrolled RRMM patients who had received ≥3 prior lines of therapy containing at least one proteasome inhibitor and one immunomodulator and whose disease had progressed after the last line of therapy (CTR20192510, NCT05066646).

As of the data cutoff date of December 31, 2022, a total of 105 participants received Equecabtagene Autoleucel at 1.0×10⁶ CAR-T cells/kg with a median follow-up of 18.07 months (IQR 12.6~21.8) and median prior four lines of therapy (range 3~23). Among the 105 patients, 69.5% (73/105) had high-risk cytogenetic abnormalities per mSMART 3.0, 13.3% (14/105) had extramedullary disease (EMD), and 11.4% (12/105) had received prior BCMA CAR-T therapy.

Efficacy: Among the 103 evaluable patients, the overall response rate (ORR) was 96.1% (99/103), with 91.3% (94/103) of those participants achieving a very good partial response (VGPR) or deeper response, and the stringent complete response/complete response (sCR/CR) rate was 77.7% (80/103). In 91 participants without prior CAR-T therapy, ORR was 98.9% (90/91), 82.4% (75/91) of patients reaching sCR/CR,the 12-month PFS rate was 85.5% (95% CI: 75.75, 91.51).

Among the 103 evaluable participants, the median time to response (mTTR) was 16 days (range 11, 179). The 12-month PFS rate was 80.0% (95% CI: 70.33,86.76). 94.2% (97/103) of patients achieved minimal residual disease (MRD) negativity, and all sCR/CR patients achieved MRD negativity. 80.8% (95% CI: 69.59,88.24) of patients sustained MRD negativity over 12 months and the median duration of MRD negativity was not reached.

Equecabtagene Autoleucel demonstrated favorable efficacy in patients with multiple myeloma (MM) who had received prior CAR-T therapy. Among the 12 MM patients who previously received CAR-T therapy, the ORR was 75.0% (9/12), with 41.7% (5/12) of those patients achieving sCR.

Safety: Among the 105 participants, 93.3% (98/105) experienced cytokine release syndrome (CRS). The majority experienced Grade 1-2 CRS, with only one experiencing ≥ Grade 3 CRS. The median time to CRS onset was 6.0 days (range 1, 13) post-infusion, and the median duration of CRS was 5.0 days (range 2, 30). Only 1.9% (2/105) of the patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS), including one grade 1 and one grade 2 ICANS, with no ≥ grade 3 ICANS. All patients with CRS or ICANS have recovered.

Expansion and Persistence: Equecabtagene Autoleucel in peripheral blood reached the peak at a median of 12 days post-infusion, with a median Cmax of 88001.13 copies/ug DNA. CAR Transgenes were still detectable in 50% (32/64) and 40% (4/10) of patients who completed follow-ups 12-month and 24-months after infusion.

Anti-CAR antibodies developed in only 20 (19.2%) patients after infusion.

Poster Presentation #2 Overview

Presentation Title: A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T treatment Conference

Session Title: Treatment of Relapsed/Refractory Multiple Myeloma

Abstract Code: P-288

Session Date and Time: September 28, 2023, 12:30 PM - 1:30 PM EEST

Patients with RRMM treated with BCMA CAR-T cell therapy frequently experience hematologic toxicity of persistent thrombocytopenia. This presentation showcases a model that was developed to distinguish between patients at high and low risk for prolonged thrombocytopenia. The model was established after analyzing the baseline clinical characteristics of the participants, PLT, C reaction protein, plasma cells in bone marrow, hemoglobin, and Ig Ferritin—which were ultimately determined to be associated with the recovery of thrombocytopenia. Patients with a model score of 5 or higher post-infusion are at a higher risk for prolonged thrombocytopenia.

The principal investigators Prof. Lugui Qiu，MD，from the Chinese Academy of Medical Science Hematology Hospital, and Prof. Chunrui Li, MD, PhD, from Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, stated, "Multiple myeloma is a hematology malignant disease with a high incidence rate, and relapse and refractory are almost inevitable after current treatments. There's an urgent unmet need for treatments that are well-tolerated and with long persistence. Equecabtagene Autoleucel, a fully human targeted BCMA CAR-T injection, has demonstrated long-lasting efficacy with a durable response. In comparison to the clinical data released at the ASCO 2023 Annual Meeting, the updated study data at IMS shows that among patients without prior CAR-T therapy, ORR remains consistently high at 98.9%. The sCR/CR rate and 12-month PFS rate also significantly improved. This suggests that with longer follow-up periods and larger groups of participants, Equecabtagene Autoleucel continues to show excellent efficacy and safety. These results are encouraging and entail a promising opportunity to reshape RRMM treatment and bring forth new hopes to patients."

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients' lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules), FUCASO® (Equecabtagene Autoleucel Injection) and SINTBILO® (Tafolecimab Injection). Additionally, we have 1 assets under NMPA NDA review, 7 assets in Phase III or pivotal clinical trials, and 18 more molecules in early clinical stage.

Innovent has also entered into 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives.

About IASO Bio

IASO Bio is a biopharmaceutical company engaged in the discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercial production.

The pipeline in the company includes a diversified portfolio of over 10 novel products, including Equecabtagene Autoleucel (a fully human BCMA CAR-T injection). Equecabtagene Autoleucel received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA) and U.S. FDA IND approval for the treatment of RR MM.

Leveraging its strong management team, innovative product pipeline, GMP production, as well as integrated manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China as well as around the world. For more information, please visit http://www.iasobio.com or www.linkedin.com/company/iasobiotherapeutics.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

美國羅克維爾和中國蘇州2023年9月29日 /美通社/ -- 信達生物制藥集團（香港聯交所股票代碼：01801），一家致力於研發、生產和銷售腫瘤、自免、代謝、眼科等重大疾病領域創新藥物的生物制藥公司，與馴鹿生物，一家致力於細胞創新藥物研發、生產和銷售的生物制藥公司，宣布在2023年國際骨髓瘤學會（IMS）年會以壁報報告形式展示了兩項研究成果：（1）全人源自體B細胞成熟抗原（BCMA）嵌合抗原受體自體T細胞（CAR-T）療法伊基奧侖賽注射液治療復發/難治性多發性骨髓瘤（RRMM）1b/2期研究（FUMANBA-1）的最新長期隨訪結果（摘要編號P-290）；（2）預測復發/難治性多發性骨髓瘤患者在抗BCMA CAR-T治療後血小板減少恢復時間延長的風險模型分析（摘要編號P-288）。

（1）摘要標題：伊基奧侖賽注射液治療復發/難治性多發性骨髓瘤（RRMM）1b/2期研究（FUMANBA-1）的最新長期隨訪結果

會議主題：復發/難治性多發性骨髓瘤的治療

摘要編號：P-290

報告時間：2023年09月28日下午12:30 - 13:30（希臘雅典當地時間）

本次報告更新了伊基奧侖賽注射液治療復發/難治性多發性骨髓瘤（以下簡稱"RRMM"）的1/2期注冊臨床研究（FUMANBA-1) 在國內14個臨床研究中心的安全性和有效性數據。

本研究（CTR20192510，NCT05066646）要求入組既往至少經歷過3線及以上治療（包含蛋白酶體抑制劑和免疫調節劑為基礎的化療方案）且末線進展的RRMM患者。截至2022年12月31日，共計納入105例接受伊基奧侖賽注射液回輸的受試者，回輸劑量為1.0×10⁶ CAR-T細胞/kg，中位隨訪時間為18.07（IQR 12.6-21.8）個月，既往治療中位線數為4（3-23）線。

在接受伊基奧侖賽注射液回輸的105例受試者中，69.5%（73/105）受試者合並mSMART3.0標准的高危細胞遺傳學異常，13.3%（14/105）受試者合並髓外漿細胞瘤，11.4 %（12/105）受試者既往接受過非全人源BCMA CAR-T治療。

有效性方面：在療效可評估的103例受試者中，總體緩解率（ORR）為 96.1%（99/103），其中91.3%（94/103）受試者達到非常好的部分緩解及以上（≥VGPR），嚴格意義的完全緩解/完全緩解（sCR/CR）率為77.7%（80/103）。91例既往無CAR-T治療史的受試者中，ORR達到98.9%（90/91），sCR/CR率更是達到了82.4%（75/91），12個月無進展生存（PFS）率為85.5%（95% CI: 75.75, 91.51）。

在療效可評估的103例受試者中，中位達緩解時間為16 (11，179)天，12個月PFS率為80.0%（95% CI: 70.33, 86.76）。94.2%（97/103）的受試者達到微小殘留病灶（MRD）陰性，其中所有sCR/CR受試者均達到MRD陰性，80.8%（95%CI：69.59, 88.24）的受試者持續維持MRD陰性超過12個月。

伊基奧侖賽注射液對既往接受過CAR-T治療的多發性骨髓瘤(以下簡稱"MM")受試者亦展現了良好的療效，12例既往接受過CAR-T治療的MM受試者中，9例獲得緩解，5例獲得嚴格意義的完全緩解。

安全性方面：105例受試者中，93.3%（98/105）受試者發生細胞因子釋放綜合征（CRS），絕大多數為1～2級CRS，僅一例受試者發生3級及以上CRS。CRS發生的中位時間為回輸後第6.0 (范圍：1-13) 天，CRS的中位持續時間為5.0（范圍：2-30）天。僅1.9%（2/105）受試者出現免疫效應細胞相關神經毒性綜合征（ICANS），其中1級和2級各1例，無≥3級ICANS。所有受試者的CRS和ICANS均得到緩解。

擴增及存續方面：外周血的CAR拷貝數中位達峰時間為回輸後12天，中位峰值水平為88001.13拷貝數/微克DNA。在隨訪達到回輸後12個月和24個月的受試者中分別有50%（32/64）和40%（4/10）的受試者仍可檢測到CAR-T細胞存續，僅有19.2%（20/104）的受試者在回輸後檢測出抗藥抗體（ADA）陽性。

（2）摘要標題：預測復發/難治性多發性骨髓瘤患者在抗BCMA CAR-T治療後血小板減少恢復時間延長的風險模型分析

會議主題：復發/難治性多發性骨髓瘤的治療

摘要編號：P-288

報告時間：2023年09月28日下午12:30 - 13:30（希臘雅典當地時間）

BCMA CAR-T細胞治療後的RRMM患者最常見的不良反應是血液學毒性，特別是持續性血小板減少。本次報告同時公布了一種用於區分長期血小板減少臨床風險等級的模型。在分析受試者的基線特征後，最終血小板、血紅蛋白、C反應蛋白、鐵蛋白以及骨髓中的漿細胞比例被確定與血小板減少症的恢復有關，並被用於建立模型。模型評分為5分或更高的患者在輸注後出現持續血小板減少的風險更高。

本次臨床研究的主要研究者，中國醫學科學院血液病醫院的邱錄貴教授和華中科技大學同濟醫學院附屬同濟醫院李春蕊教授表示："多發性骨髓瘤是血液系統常見高發的惡性腫瘤，復發耐藥在治療中幾乎不可避免，臨床亟需良好耐受性和深度持久響應的治療手段。伊基奧侖賽注射液為全人源靶向BCMA CAR-T產品，能夠更為精准地殺傷腫瘤細胞，且體內存續更持久。相較於2023年ASCO年會的隨訪數據，本次IMS大會上更新的數據中，既往未接受過CAR-T治療的受試者ORR持續保持在98.9%高位，sCR/CR率及12個月PFS率均有顯著提升，意味著在經歷更多受試者，更長的周期後，伊基奧侖賽注射液仍持續表現出令人鼓舞的療效和安全性，有望改變RRMM治療格局，給患者帶來治愈的希望。"

關於信達生物

"始於信，達於行"，開發出老百姓用得起的高質量生物藥，是信達生物的使命和目標。信達生物成立於2011年，致力於研發、生產和銷售腫瘤、自身免疫、代謝、眼科等重大疾病領域的創新藥物，讓我們的工作惠及更多的生命。公司已有10個產品獲得批准上市，它們分別是信迪利單抗注射液（達伯舒^®），貝伐珠單抗注射液（達攸同®），阿達木單抗注射液（蘇立信^®），利妥昔單抗注射液（達伯華^®），佩米替尼片（達伯坦^®），奧雷巴替尼片（耐立克^®）， 雷莫西尤單抗注射液（希冉擇^®），塞普替尼膠囊（睿妥^®），伊基奧侖賽注射液（福可蘇^®）和托萊西單抗注射液（信必樂^®）。目前，同時還有7個新藥分子進入III期或關鍵性臨床研究，另外還有17個新藥品種已進入臨床研究。

公司已與禮來、羅氏、賽諾菲、Adimab、Incyte和MD Anderson 癌症中心等國際合作方達成30項戰略合作。信達生物在不斷自研創新藥物、謀求自身發展的同時，秉承經濟建設以人民為中心的發展思想。多年來，始終心懷科學善念，堅守"以患者為中心"，心系患者並關注患者家庭，積極履行社會責任。公司陸續發起、參與了多項藥品公益援助項目，讓越來越多的患者能夠得益於生命科學的進步，用得上、用得起高質量的生物藥。至2023年3月，信達生物患者援助項目已惠及16余萬普通患者，藥物捐贈總價值數億元。信達生物希望和大家一起努力，提高中國生物制藥產業的發展水平，以滿足百姓用藥可及性和人民對生命健康美好願望的追求。

詳情請訪問公司網站：www.innoventbio.com或公司領英賬號www.linkedin.com/company/innovent-biologics/。

關於馴鹿生物

馴鹿生物是一家致力於細胞創新藥物研發、生產和銷售的生物制藥公司。公司以開發血液腫瘤細胞類藥物和抗體藥物為創新基石，向實體瘤和自身免疫疾病拓展，擁有完整的從早期發現、臨床開發、注冊申報到商業化生產的全流程能力。

公司現有10余個處於不同研發階段的創新藥物品種，其中伊基奧侖賽注射液（全人源BCMA CAR-T產品）已獲國家藥監局（NMPA）批准上市，並已獲得美國FDA批准注冊臨床，用於治療復發/難治多發性骨髓瘤。

馴鹿生物憑借其強大的管理團隊、創新的產品線、自有的GMP生產和超強的臨床開發能力，旨在提供變革性、可治愈的創新型療法，為中國乃至全球患者帶來治愈的希望。

了解更多信息，請訪問公司官網：www.iasobio.com 或領英賬號：www.linkedin.com/company/iasobiotherapeutics。

前瞻性聲明

本新聞稿所發布的信息中可能會包含某些前瞻性表述。這些表述本質上具有相當風險和不確定性。在使用"預期"、"相信"、"預測"、"期望"、"打算"及其他類似詞語進行表述時，凡與本公司有關的，均屬於前瞻性表述。本公司並無義務不斷地更新這些預測性陳述。

這些前瞻性表述是基於本公司管理層在做出表述時對未來事務的現有看法、假設、期望、估計、預測和理解。這些表述並非對未來發展的保證，會受到風險、不確性及其他因素的影響，有些是超出本公司的控制范圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展的影響，實際結果可能會與前瞻性表述所含資料有較大差別。

本公司、本公司董事及雇員代理概不承擔 (a) 更正或更新本網站所載前瞻性表述的任何義務;及 (b) 若因任何前瞻性表述不能實現或變成不正確而引致的任何責任。

HONG KONG, Sept. 28, 2023 /PRNewswire/ -- On September 26, the 2023 World Design Cities Conference (WDCC) opened at the Huangpu Riverside with the theme of "Design Beyond Creativity". The event was organized by the Shanghai Municipal People's Government. As a supporting partner, Fosun, which has been rooted in Shanghai for more than 30 years, and its subsidiaries, Yuyuan and Lanvin Group, joined the event by not only showing thoroughly the innovative designs in their products, business ecosystems and scenarios but also introduced technological innovations to press ahead with a fashion revolution, thus contributing to Shanghai's development into a world-class city of design.

During the conference from September 26 to October 2, LANVIN, the French couture house under the global fashion and luxury group, Lanvin Group, presented its 2023 Fall/Winter Collection in a five-minute fashion show infused with cutting-edge AIGC technology, presenting an online metaverse show synchronized with the offline runway. Meanwhile, Yuyuan has introduced various original design products that highlighted the original charm of Chinese culture, integrating tradition and fashion to invent a new lifestyle that features the oriental lifestyle aesthetics. The "Shanghai-Milan Twin Cities Show" will mark the opening of the 13th Shanghai Haute Couture Week. The show aims to build a two-way fashion channel and a cultural corridor between China and rest of the world in the future.

Xu Xiaoliang, Co-CEO of Fosun International and Chairman of the Shanghai International Fashion Federation, said, "Shanghai has always been a leader in the domestic design industry and a bridgehead for the entry of China's excellent design works and outstanding design enterprises into the global market. Rooted in Shanghai while developing globally, Fosun has been deeply engaged in industry operations for more than 30 years, continuously iterating innovative products that feature the oriental lifestyle aesthetics. Such products add to the happiness of family life and, at the same time, fully facilitate Shanghai's development into a world-class city of design. They contribute significantly to the growth of the city's soft power."

Two Great Shows Connecting Three Places
A Celebration of Fashion in Shanghai, Paris, and Milan

On the morning of September 26, the attention of the global design community was focused on Shanghai. The passion for fashion was high on both sides of the Huangpu River. With the theme of "Design Beyond Creativity", the 2023 World Design Cities Conference officially opened.

At the opening ceremony, LANVIN, the French couture house under the global fashion and luxury group, Lanvin Group, presented a stunning runway show with its 2023 Fall/Winter Collection. Evocations of the 1940s and the 1980s find traces in the collection, as well as references to the eighteenth century, the renaissance and the medieval periods. Injecting modern charm into classic elements for a fresh take, the collection is a rediscovery of French elegance and exuberance.

It is also the first time for LANVIN to explore the use of AIGC technology, presenting an online metaverse show synchronized with the offline runway. The seamless integration of past and present, design and technology, sparks a fresh and breath-taking experience, as LANVIN, the oldest fashion house still operating in Paris, reactivated for the present.

After the opening ceremony, the Shanghai International Fashion Federation, of which Fosun chairs, will hold a special event on the oriental lifestyle aesthetics - "Shanghai-Milan Twin Cities Show", in the main venue at the Huangpu Riverside on the evening of September 29, which is also the day of the Mid-Autumn Festival. The show will be the highlight of the World Design Cities Conference. The exciting "Twin Cities Show" will also kick off the 13th Shanghai Haute Couture Week. This year's high fashion week aims to bring forth the new through the old by turning into an "haute couture season", instead of continuing the previous "one issue per week" format of the presentation. The event not only will last longer but also will feature more diverse and exciting activities in addition to the brand shows, high-end customer salons and forums. That evening, the Shanghai International Fashion Federation will also sign a strategic agreement with the Shanghai Promotion Center for City of Design on organizing a campaign entitled "Oriental Lifestyle Aesthetics Going Global" with the aim of enabling more Chinese fashion brands to "go global".

On September 8, as an important overseas collaboration of the 2023 World Design Cities Conference, the Shanghai Fashion Day was held in Milan, Italy. The "Shanghai-Milan Twin Cities Show" is a continuation of the Shanghai Fashion Day in Milan.

The Integration of Traditional Culture and Innovative Design Demonstrates the Charms of Oriental Lifestyle Aesthetics

In the Hall of Industry of this year's World Design Cities Conference, Yuyuan, which owns 17 time-honored Chinese brands and many vintage brands, brings the original design of a variety of brands, such as Shanghai Watch, Seagull Watch, Dongjia, WEI Beauty, and Laochenghuangmiao, covering a wide variety of products such as wristwatches, handicrafts, cosmetics, foods and beverages, and featuring their packaging designs.

The Thousand Miles of Rivers and Mountains model of Shanghai Watch's Renaissance-Danqing Series of products is inspired by the Gu embroidery's "integration of painting theory into embroidery", showing paintings on the watch dial. Seagull Watch's Great Han Dynasty-General of the Flying Cavalry Collection is inspired by Chinese history, manifesting the "spirit of China" throughout the entire collection. The craftsmen of Dongjia and Suzhou Museum jointly launch the Secret Color Porcelain Lotus Lamp Gift Box, inspired by the "Secret Color Lotus Bowl" of Yue Kiln of the Five Dynasties, which is the treasure of Suzhou Museum. The cosmetics brand, WEI Beauty, launches a new series of Ming Dynasty Imperial Collection, inspired by the "Blue-and-White Dragon and Phoenix Box with Cover" during the reign of the Wanli Emperor from the artifact collection of the China Ceramics Museum in Jingdezhen.

In addition to the excellent design works from various brands, "Made in Yuyuan", an important future intellectual property of Yuyuan, has also been unveiled in advance at the conference. "Made in Yuyuan", which consists of Yuyuan's seven types of dim sum, is exhibited at this year's World Design Cities Conference. The designs on the card boxes as the packaging of the food is based on the series of original illustrations of Yuyuan's time-honored brands and they can bring consumers pleasant surprises when they "unbox" the breakfast for a week.

Moreover, Fosun and Yuyuan will also bring the oriental lifestyle aesthetics from Shanghai, China to Paris, France. On September 26, the Conférence de présentation du Festival Dragons et Lanternes was held in Paris as the special overseas promotional activity of the 2023 World Design Cities Conference. The event officially announced the Festival Dragons et Lanternes' debut on the world stage as one of the representative cultural and artistic activities of the Chinese New Year. The 72-day Festival Dragons et Lanternes in France is scheduled to take place from late 2023 to early 2024, integrating the traditional Chinese cultural elements with the global fashion trends.

HONG KONG, Sept. 28, 2023 /PRNewswire/ --  Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azacitidine for treatment of patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS). The upcoming study, known as a randomized, double-blind, global multi-center Phase II study, is set to be conducted in the United States.

Based on the favorable safety profile and remarkable efficacy of AK117 in combination with azacitidine for the treatment of newly diagnosed higher-risk MDS patients, as showcased in previous studies, and the strong demand from MDS patients worldwide, Akeso has conducted comprehensive scientific communication and discussions with the FDA. Akeso believes that this study will facilitate the global development process for AK117.

"With more time and space, we will consistently implement a comprehensive international strategy to explore and advance our innovative therapies. For the benefit of more patients, we will leverage global resources to improve the success rate of AK117." Said Dr. Michelle Xia, the founder, Chairwoman, CEO, and President of Akeso.

Anemia is a significant symptom of MDS, and effectively managing anemia and minimizing blood transfusion are crucial aspects of disease control. In contrast to other anti-CD47 antibody drugs, which have been reported to worsen anemia in MDS patients by causing RBC hemagglutination, AK117 eliminated RBC hemagglutination and also enabled to maintain full effectiveness of CD47 blockade on tumor cells, which resulted in excellent antitumor efficacy and favorable safety profile of AK117.

The previous studies of AK117 in combination with azacitidine showed positive results in patients with newly diagnosed higher-risk MDS. AK117 reduced anemia and transfusion requirements among MDS patients, and demonstrated a favorable safety profile and remarkable efficacy. These findings position AK117 as a promising therapeutic option for MDS patients worldwide.

Notably, Akeso is consistently advancing the development of AK117 as a therapeutic agent in combination with various agents such as PD-1/CTLA-4 and PD-1/VEGF, for treatment of multiple hematologic malignancies and solid tumors.

About Ligufalimab (AK117)

AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors.

內置Leica光學鏡頭 延續人文影像精髓 

香港2023年9月27日 /美通社/ -- 小米宣佈最新的旗艦手機Xiaomi 13T Series 正式登陸香港，是次系列專為喜歡人文影像攝影的用戶而設。Xiaomi 13T Series加入了Leica的專業光學鏡頭，讓用戶捕足更真實的Leica影像精髓。系列更配備先進的性能架構、持久的電池壽命，以及清晰超色準的螢幕，確保用戶無論在拍攝照片、觀看影片或日常使用中享受最卓越的手機體驗。

Xiaomi 13T Series 由9月27日下午2時至9月29日於全線小米之家、小米之家專賣店、小米官網mi.com 、香港各大運營商和零售商門市及網站同步接受預訂, 並享有以下優惠。

適逢小米之家旺角創興廣場店於重新裝修後隆重開幕，為隆重其事，Xiaomi 13T Series特設於9月30日正式發售。當日於小米之家旺角創興廣場店購買Xiaomi 13T Series，設有獨家優惠，首200名購買，除了獲贈旅攝套裝 （價值港幣$ 599），更可額外獲得小米無線行動電源 10000 22.5W（價值港幣$ 179）。

開幕當日，我們特別邀請了小米集團副總裁兼首席財務官林世偉先生、小米集團獨立非執行董事唐偉章先生 、天星銀行行政總裁及執行董事胡偉先生、小米集團東亞地區部總經理李剛健先生、著名男藝人陳豪先生及多位合作夥伴出席剪綵及祝酒儀式。當天店內更特設Xiaomi 13T Series任玩即影即印影像區，體驗與Leica 聯乘專業光學的攝人魅力。更有大量手機及家電產品提供優惠酬賓，最低46折，讓顧客有全新的門市體驗外，同時滿載而歸。

以專業的Leica攝影能力打造您的完美傑作
小米向來留意用戶的需求，是次Xiaomi 13T Series帶來了專業級的攝影體驗，回應新一代智能手機用戶對創意的熱情。Xiaomi 13T Pro和Xiaomi 13T均搭載了三鏡頭配置，其中包括與Leica共同開發的Summicron鏡頭。三鏡頭配置包括5,000萬像素廣角鏡頭，等效焦距為24mm，同時配備7P非球面鏡片，能夠攝取更多光線和細節，支援高動態範圍拍攝；另配有5,000萬像素遠攝鏡頭，等效焦距為50mm；以及1,200萬像素超廣角鏡頭，等效焦距為15mm，非常適合拍攝全景照片和壯麗的風景。Xiaomi 13T Pro和Xiaomi 13T的鏡頭均採用100% DCI-P3技術，具有更寬廣的色彩範圍，讓用戶體驗經典Leica品質，輕易捕捉每一個珍貴的神奇時刻。

Xiaomi 13T Series 提供兩種原創的Leica攝影風格：Leica Authentic Look和Leica Vibrant Look，以自然色調、強烈對比和陰影，配備經典的Leica影像美學，助用戶創造出驚人的影像可能。六款Leica濾鏡高度還原Leica影像傳奇色彩，包括參考自 LeicaM-Typ240 Film Mode的最新 Leica Sepia 和 Leica Blue，為照片構圖提供更多選擇，讓用戶盡情創作。

Xiaomi 13T Series還加入了首次應用於Xiaomi 13 Ultra的Pro mode自訂攝影風格功能，允許用戶在拍攝前調整影調、色調和質感，能保留更多細節和豐富的色彩以供後期處理。同時，用戶還可以保存自己的喜愛預設，打造獨特的個人攝影風格。透過Xiaomi ProFocus技術，從動態物件（如狗和鳥類）的特寫照片，到迷人的人物和風景影像，Xiaomi 13T Series讓攝影師輕易仔細地捕捉到這些動人場景。

帶您進入驚艷的全新影片拍攝境界
Xiaomi 13T Pro完美實現用戶的非凡拍攝夢想。沉浸於10-bit LOG 4:2:0 H.265影片錄製的世界，享受前所未有對色彩和細節的掌控。配合預設的Rec.709 LUT，讓用戶的影片增添了更專業的感覺，令影片呈現出無與倫比的色彩準確度和視覺深度。

提供個人化體驗一向是小米智能設備的核心，Xiaomi 13T Pro旨在讓用戶自由展現獨特的視覺風格。用戶可以將喜愛的LUT風格導入，為所拍攝的影片賦予個人的獨特風格和魅力。此外，Xiaomi 13T Pro具備8K影片拍攝能力，確保每一個場景、每一個細節都以電影級的品質永久記錄下來。5,000萬像素廣角相機同時支持光學防手震（OIS）和電子防手震技術（EIS），確保影片即使在運動中拍攝也能保持穩定。

Xiaomi 13T的後置相機支援全焦段4K影片錄製，並搭配快速簡易的編輯功能。只需進入Xiaomi Gallery應用程式中的Video editor，及調校至Pro mode，便可輕鬆編輯字幕和額外音軌作為獨立軌道，非常適合創作社交媒體短片或生活紀錄短片。

盡情沉浸於令人嘆為觀止的視聽體驗中
Xiaomi 13T Pro和Xiaomi 13T的螢幕將全面提升，畫面清晰和色彩生動，讓用戶的觀影體驗更上一層樓。Xiaomi 13T Series配備6.67英吋的CrystalRes螢幕，支援高達144Hz的刷新率⁴和1.5K（2,712 x 1,220）解像度，為用戶呈獻驚艷的色彩表現。同時，Xiaomi 13T Series採用了1,200nits的高亮度螢幕，峰值亮度高達2,600nits⁵。此外，Xiaomi 13T Series提供100％的DCI-P3色域覆蓋率⁶，支援680億種色彩，提供全方位的HDR10+相容性。種種配置均增強了圖像光暗部份的對度，還原了細節的真實質感，並提供更平衡的色彩飽和度。從自拍、肖像到影片和生活紀錄短片，內容創作者都能輕易打造出專業的影視內容；同時，Xiaomi 13T Series支援 Dolby Atoms®，內置雙揚聲器，讓用戶完全沉浸在自己喜愛的內容中。

超卓性能 優越體驗
Xiaomi 13T Pro和Xiaomi 13T均搭載了廣泛的功耗提升和持久的電池壽命，讓用戶能夠享受更快速且更高效的智能手機體驗。

Xiaomi 13T Pro採用MediaTek Dimensity 9200+晶片組，搭載八核心旗艦CPU，主頻高達3.35GHz。同時，亦內置Arm Immortalis-G715 GPU，能夠提升圖像處理效能，使遊戲體驗更加順暢，且無需擔心電池續航問題。Xiaomi 13T則採用MediaTek Dimensity 8200-Ultra晶片，採用最新的 TSMC 4nm製程，締造了出色的功耗效能，同時提升了CPU和GPU的性能。Xiaomi 13T Series亦搭載了5,000mm²的VC不銹鋼散熱板，讓散熱更為快速。

Xiaomi 13T Pro支援 Xiaomi 120W HyperCharge技術，能夠在短短19分鐘內充電滿100%⁷。兩款手機設備都具備快速充電功能，Xiaomi 13T Pro在僅5分鐘內能充電至36%，而Xiaomi 13T則能充電至21%⁷。

Xiaomi 13T Series採用了ISP（內部短路保護裝置）、SOA（安全運作區域）、DTPT（動態調整電壓技術）等技術，確保5,000mAh （typ）大容量電池的安全性。

時尚流行外型 配合IP68防水防塵等級⁸
Xiaomi 13T Pro 和 Xiaomi 13T均擁有IP68防水防塵等級⁸，設計堅固耐用，共有三種顏色以供選擇，包括黑色、雪山藍、原野綠。雪山藍機背採用了優質的Xiaomi BioComfort仿皮革，質感柔軟細緻，手感舒適。而原野綠和黑色機背則使用了亮面玻璃設計，令外型更時尚奢華。Xiaomi 13T Series的每個特點都能讓你放心地捕捉、觀賞和沉浸在每個令人振奮的生活時刻。

全球「Xiaomi Imagery Awards 小米影像大賽 2023」拍出你的故事
全球「Xiaomi Imagery 小米影像大賽 2023，Supported by Leica」於9月26日全面展開

小米今日除了帶來Xiaomi 13T Series，讓更多用戶享受Leica影像魅力，亦宣布全球「Xiaomi Imagery 小米影像大賽 2023，Supported by Leica」同時開始，今年全球性攝影大賽全面升級，共分攝影組與短片組，其中攝影組再設置10個主題，邀請三位國際攝影大師擔任評審，鼓勵使用Xiaomi、Redmi手機的創作者積極投稿，得獎者可獲得最高$10,000美金創作基金外，還有機會成為Xiaomi Studio合作攝影師等其他商業製作機會，邀請全球Xiaomi、Redmi手機創作者透過多元豐富的影像，傳遞真切人文情感。

小米自2021年開始舉辦全球Xiaomi Imagery Awards，2022年攝影大賽囊括自然、人像、建築、生活方式、夜景、運動與微距共7大主題，共徵集來自全球超過上萬件的優秀作品，在四位專業的國際評審共同評選下，選出由Xiaomi 11T、Redmi Note 11 Pro、Redmi Note 9S等拍攝出的壯闊畫面與珍貴時刻。

而今年「Xiaomi Imagery 小米影像大賽 2023，Supported by Leica」更擴大舉辦，攝影組以「精彩瞬間」、「人像」、「熱情」、「期待」、「成長」、「趣味」、「歡慶」、「地方風情」、「動植物」與「旅途之中」等10大情感主題，徵集拍出緊扣「Your vision, your story」的感情豐富作品，並將邀請3位國際攝影專家進行評選；而短片組則以敘事流暢度、表現、製作設計、視覺構圖與電影攝影、音效強化、剪輯和視覺強化等標準，邀請國際級導演評選，短片組首獎將可獲美金$10,000的創作基金與Xiaomi Studio合作攝影師機會。

以「Your vision, your story」為主軸的「Xiaomi Imagery 小米影像大賽 2023，Supported by Leica」，即日起至2023年12月31日開放報名，只要是使用Xiaomi與Redmi品牌手機創作的原創作品均可參加，參賽者可以選擇多個組別報名，但同一張作品僅可參與一個單元，歡迎喜歡使用手機來記錄生活、分享故事的攝影創作者報名！更多「Xiaomi Imagery Awards 小米影像大賽 2023」詳情請參考：https://event.mi.com/cn/xiaomiImageryawards/

高清圖片下載

Xiaomi 13T Pro及Xiaomi 13T規格表

備註：

1. 數量有限，先到先得，送完即止。
2. 優惠期由即日起至2024年9月30日期間。
3. 優惠即日起至2024年7月31日期間。此優惠僅供新用戶使用，並須遵守適用的條款和條件。 您可以隨時靈活取消。
4. 螢幕最高支援144Hz刷新率。 不同應用介面和遊戲畫質下，螢幕更新率可能略有不同。 請參考實際體驗。
5. 數據由小米內部實驗室測試，實際結果可能有所差異。 個別產品之間的實際測量結果可能會有所不同。 所有規格均以實際產品為準。 在升壓模式下測試 19 分鐘達到 100%。
6. 100% DCI-P3 覆蓋範圍可能會根據顯示器的亮度而有所不同。
7. 數據由小米內部實驗室測試，實際結果可能有所差異。 個別產品之間的實際測量結果可能會有所不同。 所有規格均以實際產品為準。 在升壓模式下測試 19 分鐘達到 100%。
8. 此設備經認證僅在與正常使用條件不對應的特定實驗室條件下具有防水和防塵功能。 保固不涵蓋測試條件以外的條件造成的液體損壞。 入口保護可能會因磨損、物理損壞和/或維修所需的拆卸而惡化。 更多資訊，請查看小米官網。
9. AdaptiveSync支援30/60/90/120/144Hz之間切換。
10. 觸控採樣率可能會根據顯示幕上的內容而有所不同。
11. 使用 eSIM 需要無線服務方案。 此服務計劃可能會受到某些關於切換服務提供者和漫遊的使用限制（即使在合約到期後）。 eSIM 的可用性可能會因國家/地區和營運商的不同而有所不同。 如需了解更多詳情，請聯絡您的電信業者以取得更多資訊。
12. Wi-Fi 7/Wi-Fi 6功能可能會因區域可用性和本地網路支援而異。 Wi-Fi 連線（包括 Wi-Fi 頻段、Wi-Fi 標準和在IEEE 標準 802.11 規範核准下的其他功能）可能會根據區域可用性和本地網路支援而有所不同。 在適用的情況下，可以透過 OTA 添加該功能。
13. NFC 的可用性可能因市場而異。

關於小米集團
小米集團成立於2010年4月，2018年7月9日在香港交易所主板掛牌上市（1810.HK），是一家以智能手機、智能硬件和IoT平台為核心的消費電子及智能製造公司。

胸懷「和用戶交朋友，做用戶心中最酷的公司」的願景，小米致力於持續創新，不斷追求極致的產品服務體驗和公司運營效率，努力踐行「始終堅持做感動人心、價格厚道的好產品，讓全球每個人都能享受科技帶來的美好生活」的公司使命。

小米目前是全球領先的智能手機品牌之一。截至2023年6月，全球MIUI月活躍用戶6.06億。同時，小米已經建立起全球領先的消費級AIoT（人工智能和物聯網）平台，截至2023年6月30日，小米AIoT平台已連接的IoT設備（不包括智能手機、筆記本電腦及平板）數達到6.55億。集團業務已進入全球逾100個國家和地區。2023年8月，小米集團連續五年進入《財富》「世界500強排行榜」（Fortune Global 500），位列第360名。

小米集團目前為恒生指數、恒生中國企業指數、恒生科技指數及恒生神州50指數成份股。

有關小米公司的更多信息，請瀏覽https://blog.mi.com/en/。

#xiaomhk

官方網站：http://mi.com/hk/
Instagram帳號：@xiaomi.hk 
Facebook專頁：小米香港 Xiaomi Hong Kong

香港2023年9月27日 /美通社/ -- 2023年9月26日，由上海市人民政府主辦，主題為「設計無界，造化萬象」的2023世界設計之都大會（WDCC）在上海黃浦濱江開幕。植根上海三十餘年的復星作為支持夥伴，攜旗下豫園股份與復朗集團深度參與，不僅全方位展示產品、生態、場景等多方面的創新設計，更引入科技創新推動時尚革新，為上海建設世界一流「設計之都」助力。

9月26日至10月2日大會期間，復朗集團旗下法國高級時裝屋浪凡（LANVIN）在黃浦江畔上演開幕大秀，重新演繹法式優雅與活力，以科技創新方式呈現品牌在當下語境的全新風貌；豫園股份帶來多款凸顯中華文化的原創設計作品，將傳統與時尚融合，以東方生活美學引領新的生活方式；「上海·米蘭－雙城映畫」秀演，標誌着第十三屆上海高級訂製周啟幕，未來將構建中國－全球雙向時尚通道和文化走廊。

復星國際聯席CEO、上海國際時尚聯合會會長徐曉亮表示：「上海一直是國內設計產業的引領者，也是中國向世界輸送優秀設計作品、傑出設計企業的橋頭堡。植根於上海、發展於全球，復星三十餘年來始終深耕產業運營，不斷疊代充滿東方生活美學的創新產品，助力家庭幸福生活，同時全力支持上海建設成為世界一流『設計之都』，為城市軟實力的增長帶來積極意義。」

兩場大秀串聯三地，上海、巴黎、米蘭共襄時尚盛宴

9月26日上午，全球設計界的目光聚焦上海，浦江兩岸時尚熱情高漲。以「設計無界，造化萬象」為主題的2023世界設計之都大會正式拉開帷幕。

在開幕式現場，全球時尚奢侈品集團Lanvin Group（復朗集團）旗下法國巴黎高級時裝屋LANVIN攜2023年秋冬系列驚艷亮相。秀場造型以1940和1980年代為主題，並從18世紀、文藝復興以及中世紀時期汲取靈感，用復古壁畫和花卉靜物點綴設計，並注入現代魅力，令經典元素煥然一新。

採用經典元素外，LANVIN首次使用AIGC技術，在線下走秀同時，線上舉辦元宇宙秀場，創造身臨其境的數字環境，並結合新穎設計和人工智能技術帶來非凡體驗。過去與現在相融，西方美學與東方文化碰撞，設計與科技交互，激發出令人驚喜的火花，LANVIN在黃浦江畔重新演繹了經典時裝屋的優雅與活力。

開幕式活動後，作為本屆世界設計之都大會的重磅環節，9月29日中秋節當晚，由復星擔任會長單位的上海國際時尚聯合會，將舉辦東方生活美學專場活動——「上海·米蘭－雙城映畫」，將在黃浦濱江主會場驚艷亮相。伴隨着「雙城映畫」的精彩秀演，第十三屆上海高級訂製周也將在當晚啟幕。本屆高訂周推陳出新，一改以往一期一周的呈現形式，創新變身「高訂季」，除了舉辦時間更長之外，形式也不限於品牌秀、高客沙龍、論壇等，將增添更豐富多彩的活動形式。當晚，上海國際時尚聯合會還將與上海設計之都促進中心簽署了「東方生活美學走出去」戰略協議，帶領更多中國時尚品牌「走出去」。

此前9月8日，作為2023世界設計之都大會的海外重要聯動活動——SHANGHAI FASHION DAY（上海時尚日）在意大利米蘭舉行，而「上海·米蘭－雙城映畫」正是米蘭「上海時尚日」的成果延續。

傳統文化融合創新設計，呈現東方生活美學魅力

在本屆世界設計之都大會產業館中，旗下擁有17個中華老字號和一眾優質品牌的豫園股份帶來了旗下上海錶、海鷗錶、東家、WEI蔚藍之美、老城隍廟等多個品牌的原創設計作品，涵蓋腕錶、工藝品、化妝品、飲食等產品和包裝設計的方方面面。

上海錶的復興·丹青系列千里江山款以顧繡「融畫理入繡」為設計靈感，將畫作融於錶盤之上；海鷗錶的大漢雄風·驃騎將軍系列從中國歷史中取材，將「中國精神」貫穿始終；東家手藝人與蘇州博物館攜手推出的秘瓷蓮花盞禮盒，靈感來源於蘇州博物館鎮館之寶五代越窯「秘色蓮花碗；化妝品品牌WEI蔚藍之美推出的明王朝御容系列新品，靈感來源於景德鎮中國陶瓷博物館館藏文物「明萬曆青花龍鳳紋蓋盒」。

除了來自各品牌的優秀設計作品之外，豫園股份未來的重要IP「豫園製造」也在本次展會上提前揭秘。「豫園製造」——豫園七點心參展本屆世界設計之都大會，該設計以豫園老字號原創插畫系列為紙盒外觀，配以七種不同的美味點心，為消費者帶來一周早餐開箱式的「奇妙」體驗。

此外，復星和豫園股份還將東方生活美學從上海帶至法國巴黎。9月26日，2023世界設計之都大會的海外專場推廣活動——法國豫園燈會推介會在法國巴黎舉行，正式宣佈「豫園燈會」這一中國新春文化藝術活動的設計代表作品，首次出海走向世界舞台。為期72天的法國豫園燈會計劃於2023年底至2024年初舉辦，將中國傳統文化元素與全球時尚潮流完美融合。

上海2023年9月27日 /美通社/ -- 北京時間9月26日，啟明創投投資企業、中國領先的一站式汽車服務平台途虎養車在香港交易所主板成功上市。途虎養車（09690.HK）發行價為28港元/股，市值約227.46億港元。

作為早期投資方，啟明創投於2014年開始投資，是途虎養車B輪、C輪、E輪投資方。途虎養車的成功上市，也是啟明創投2023年開年以來迎來的第七個IPO。

途虎養車成立於2011年，是中國領先的線上線下一體化汽車服務平台，依托以客戶為中心的模式及流暢的供應鏈，提供數字化、按需服務的客戶體驗，滿足車主多樣化的產品和服務需求，打造一個由車主、供貨商、汽車服務門店和其他參與者組成的汽車服務平台。

途虎養車通過創新的線上線下一體化商業模式、數字化的客戶服務體驗和行業解決方案、領先的運營規模以及專有汽車服務技術支持系統在運營中的開發和應用，脫穎而出。截至今年上半年，途虎養車App及線上擁有超過1億名註冊用戶，平均月活約1000萬人，是中國汽車服務供應商聚集的最大車主社區。此外，途虎養車在全國擁有超過5100家途虎工場店和超過2萬家合作門店，覆蓋全國大部分地級市。

途虎養車創始人兼CEO陳敏表示：「今年是途虎養車成立的第十二年，我們有幸見證和參與了中國汽車服務市場的快速發展。途虎上市是一個新的起點，未來我們會繼續以真誠開放的心態、務實嚴謹的姿態，為市場提供更多、更好的產品和服務。」

啟明創投創始主管合夥人鄺子平表示：「早在2014年，啟明創投就關注到途虎養車這個品牌，其以新穎的廣告和良好的用戶體驗吸引了大量用戶。同時途虎養車團隊的超強執行力和敏銳的市場洞察力，也讓啟明創投對公司發展充滿信心。上市是途虎養車發展的關鍵節點之一，希望公司未來能夠為更多不同類型的車主提供更多的產品更好的服務，在上市後取得更好的發展。」

關於啟明創投

啟明創投成立於2006年，先後在上海、北京、蘇州、香港，西雅圖、波士頓和舊金山灣區設立辦公室。目前，啟明創投旗下管理11只美元基金，7只人民幣基金，已募管理資產總額達到95億美元。自成立至今，專注於投資科技及消費(Technology and Consumer, T&C)、醫療健康(Healthcare)等行業早期和成長期的優秀企業。

截至目前，啟明創投已投資超過530家高速成長的創新企業，其中有超過200家分別在美國紐交所、納斯達克，香港交易所，上交所及深交所等交易所上市，及合併等退出，有70多家企業成為行業公認的獨角獸和超級獨角獸企業。

啟明創投投資企業中，很多已經成長為各自領域中最具影響力的公司，包括小米集團（01810.HK）、美團（03690.HK）、嗶哩嗶哩（NASDAQ:BILI, 09626.HK）、知乎（NYSE:ZH, 02390.HK）、石頭科技（688169.SH）、甘李藥業（603087.SH）、泰格醫藥（300347.SZ, 03347.HK）、再鼎醫藥（NASDAQ:ZLAB, 09688.HK）、康希諾生物（688185.SH, 06185.HK）、Schrödinger（NASDAQ:SDGR）、惠泰醫療（688617.SH）、諾輝健康（06606.HK）、啟明醫療（02500.HK）、三友醫療（688085.SH）、艾德生物（300685.SZ）、貝瑞基因（000710.SZ）、神州細胞（688520.SH）、圓心科技、康締亞、信念醫藥、文遠知行、壁仞科技、優必選等。

此新聞稿由啟明創投發佈。

SHANGHAI, Sept. 26, 2023 /PRNewswire/ -- Shanghai Electric (SEHK:2727, SSE:601727) recently showcased its offerings at the China International Industrial Fair 2023 ("CIIF") held at the National Convention and Exhibition Center (Shanghai) from September 19-23, 2023, under the theme A Zero-Carbon Future For All, with a focus on the three major pillars of smart energy, intelligent manufacturing, and digital intelligence integration. Shanghai Electric impressed visitors with a demonstration of its equipment manufacturing digital transformation results that integrate digital intelligence, wind power, photovoltaic power, energy storage, and allocated solutions, among other world-class innovative technologies that have the capacity to empower a zero-carbon future for all.

"When China proposed its 3060 dual carbon targets, which aim to achieve peak carbon emissions by 2030 and carbon neutrality by 2060, Shanghai Electric began developing a comprehensive new power system and a three-dimensional zero-carbon industrial park solution," Liu Ping, President of Shanghai Electric Group, said in his speech at CIIF. "Our allocated wind, solar, and storage integrated solutions, digital intelligence integration, and smart carbon management system that showcasing at CIIF will empower more customers and partners around the world to achieve their carbon reduction and zero-carbon development goals."

On the opening day of CIIF, Shanghai Electric signed strategic cooperation agreements with AVIC Commercial Aviation Engine Co., Ltd. and the Yangtze River Delta National Innovation Center, opening a new comprehensive collaboration chapter.

Empowering the energy transformation of the industrial supply chain through the release of three major smart industry solutions

With decades of experience in the development of technological innovation in the energy industry, Shanghai Electric has successively released three major smart industry solutions, namely, Energy Carbon Smart Butler, SEunicloud Industrial Internet Platform 4.0, and Zero Carbon Industrial Park. It has also developed an "energy carbon steward" based on its industrial internet platform that realizes the transformation from energy expert to energy carbon steward. This solution is oriented to the entire life cycle of planning, construction and operation, and deeply integrates equipment and information technology to meet the general and specific needs of various customers, ranging from enterprises to industrial parks, factories, warehouses, schools, and cities, among others.

Powering up integrated wind, solar, storage, and distribution smart energy solutions

Shanghai Electric's integrated wind and solar storage solutions provide one-stop integrated equipment and services for multiplexed, high-quality energy storage and conditioning. Energy, compressed air energy storage, lithium battery energy storage, liquid flow energy storage and other energy storage, technology equipment can realize frequency and peak regulation functions at a granular level.

Additionally, Shanghai Electric also demonstrated its three-dimensional zero-carbon industrial park, which provides industrial parks with everything from the design and construction of green industrial plants to distributed new energy supply, from green intelligent manufacturing lines to industrial-driven energy efficiency improvements. It also demonstrated cases of carbon reduction at the source, creating innovative demonstrations of multi-functional complementarity throughout the industry and setting a leading benchmark for green, zero-carbon, smart factories.

Driving the optimization of intelligent manufacturing and showcasing next-gen equipment technology across multiple industries

At CIIF, Shanghai Electric showcased complete line solutions for lithium battery smart factories, rail transit automation control systems, large-scale precision grinders, and mid-to-high-end CNC machine tools for the new energy lithium battery industry, as well as urban rail transit and industrial machine tools. Additionally, Shanghai Electric displayed equipment such as large F-class heavy-duty gas turbines, high-temperature gas-cooled reactors, ultra-high voltage transformers, and intelligent universal air circuit breakers.

In the field of new energy vehicles, Shanghai Electric provides full industry chain services, including low-carbon industrial plant design, intelligent production lines for vehicle and battery pack assembly, new energy vehicle batteries, and other components. For the aviation industry, Shanghai Electric can provide key products and integrated services such as automated drilling and riveting systems and assembly lines, as well as important aircraft subsystems and components such as aircraft instrumentation and control systems, aviation fasteners, and engine blades. For customers in the shipping industry, Shanghai Electric has increased supply performance in the fields of marine ballast water devices, marine power systems, and supporting equipment, all with huge development potential.

Moving forward, Shanghai Electric will continue to leverage its advantages in advanced equipment manufacturing and smart energy while working closely with industry chain organizations to promote zero-carbon development.

To watch Shanghai Electric's Highlight Video of its CIIF 2023 exhibition, please visit: https://www.facebook.com/ShanghaiElectric/videos/1486796252116909/.

香港2023年9月26日 /美通社/ -- 全球領先指數公司富時羅素（FTSE Russell）近日公佈了復星國際有限公司（香港聯交所股份代號：00656，簡稱「復星國際」）最新的 ESG（環境、社會及管治）評級結果。

復星國際富時羅素FTSE ESG評分持續領先全球行業及中國企業平均水準

2023年，復星國際富時羅素FTSE ESG評分由3.0分提升至3.8分，持續領先全球行業平均水準（2.4分）及中國企業平均水準（1.6分），並連續入選富時羅素社會責任指數（FTSE4Good Index Series）成份股。

FTSE ESG 評級重點覆蓋企業治理、環境和社會議題。根據此次評級結果，復星國際在環境議題、社會議題及治理議題的得分均領先行業平均水準及中國企業平均水準。其中，復星國際在環境供應鏈、污染物與資源、人權與社群、社會供應鏈、企業治理、風險管理領域均達到了4.0及以上高分，同時，反貪腐繼續取得了5.0滿分，勞工標準亦首次獲得了5.0滿分。

復星國際此次評級分數的大幅提升，及連續入選富時羅素社會責任指數成份股的優異成績，充分體現了資本市場對公司ESG管理能力的高度認可，將持續吸引更多秉持ESG責任投資理念的投資機構的關注。

復星國際ESG評級優異，獲市場廣泛認可

近年來，復星國際的ESG評級成績不斷突破，彰顯了卓越的可持續發展能力。截至目前，復星國際恆生ESG評級為AA-，並於2023年首次入選恆生可持續發展企業指數成份股； MSCI ESG評級為AA，是大中華地區唯一一家MSCI ESG評級為AA的綜合型企業；標普全球企業可持續發展評估成績排名超過91%的全球同業，入選標普全球《可持續發展年鑑2023（中國版）》及獲頒「行業最佳進步企業」標徽。

未來，復星將一如既往地重視ESG管理工作，在企業發展中踐行「修身、齊家、立業、助天下」的創業初心，積極承擔更多社會及環境責任，持續創造價值、回報社會，助力社會發展。同時，在社會各界致力於減緩氣候變化、促進全球可持續發展的趨勢下，復星將繼續聯合復星全球生態落實ESG理念，加強復星氣候韌性，共同推進碳中和。

關於富時羅素社會責任指數

富時羅素社會責任指數(FTSE4Good Index Series) 於2001年創立，是首個度量符合全球公認企業責任標準的公司表現的指數系列，旨在發現在環境、社會與治理（ESG）的實踐方面表現傑出的公司，並對其成績進行表彰。該指數因其極具透明度的指數管理和計算準則，成為投資顧問、資產擁有人、基金經理、投資銀行、證券交易所和經紀商的寶貴工具，幫助他們評估或創建符合社會責任價值觀的投資產品。符合入選富時羅素社會責任指數資格的企業，需就多個企業責任主題落實相關措施，包括環境管理、緩解氣候變化、反貪污腐敗、維護人權、勞工權利和供應鏈的勞工標準等，並符合嚴格的全球準則，才可成為富時羅素社會責任指數的成分股。

關於復星

復星創立於1992年，經過逾30年發展，已成為一家創新驅動的全球家庭消費產業集團。秉持讓全球家庭生活更幸福的使命，復星致力於服務全球十億家庭客戶，戰略聚焦健康、快樂、富足的幸福生態系統。2007年復星國際在香港聯交所主板上市（股份代號：00656.HK），截至2023年6月30日，公司總資產達人民幣8,349億元，MSCI ESG評級為AA，是大中華地區唯一一家MSCI ESG評級為AA的綜合型企業。

HONG KONG, Sept. 26, 2023 /PRNewswire/ -- The world's leading index company, FTSE Russell, recently announced the latest ESG (Environmental, Social and Governance) rating results of Fosun International Limited (HKEX stock code: 00656, "Fosun International").

Fosun International's FTSE Russell ESG rating consistently outperforms the global industry average and the country average

In 2023, Fosun International's FTSE Russell ESG rating improved from 3.0 to 3.8, consistently outperforming the global industry average (2.4) and the country average (1.6), while maintaining its inclusion in the FTSE Russell FTSE4Good Index Series.

The FTSE Russell ESG rating focuses on corporate governance, environmental, and social issues. According to the latest rating results, Fosun International outperformed the industry average and the country average across environmental, social, and governance issues. Specifically, Fosun International received scores of 4.0 and above in the fields of Environmental Supply Chain, Pollution & Resource, Human Rights & Community, Social Supply Chain, Corporate Governance, and Risk Management. Furthermore, it achieved a perfect score of 5.0 in Anti-Corruption and, for the first time, a full score of 5.0 in Labor Standards.

The substantial improvement in Fosun International's ESG rating and its continued inclusion in the FTSE4Good Index Series highlight the capital market's strong recognition of the Company's ESG management capabilities. This recognition is expected to attract greater attention from investment institutions committed to ESG-responsible investment principles.

Fosun International's outstanding ESG ratings remark its wide recognition by the market

In recent years, Fosun International's ESG ratings have continued to excel, underscoring its outstanding sustainability performance. As of now, Fosun International received an AA- rating in the Hang Seng Sustainability Index and has been included in the Hang Seng Corporate Sustainability Index for the first time in 2023; it received an AA MSCI ESG Rating and was the only conglomerate in Greater China with such rating; it outperformed 91% of its global peers in the S&P Global Corporate Sustainability Assessment, was included in S&P Global's Sustainability Yearbook 2023 (China Edition), and was recognized as "Industry Mover".

Looking ahead, Fosun will continue to prioritize ESG management, remaining committed to its founding mission of "Self-improvement, Teamwork, Performance, and Contribution to Society". The Company will actively undertake more social and environmental responsibilities, create sustained value, give back to society and contribute to social development. In light of the global commitment to mitigating climate change and advancing sustainable development, Fosun will collaborate with its global Fosun ecosystem to implement ESG principles and enhance climate resilience, collectively advancing towards carbon neutrality.

About FTSE4Good Index Series

Launched in 2001, the FTSE4Good Index Series is the first index series to measure the performance of companies that meet globally recognized corporate responsibility standards. It aims to identify and recognize companies demonstrating strong Environmental, Social and Governance (ESG) practices. Transparent management and clearly-defined ESG criteria make FTSE4Good indexes suitable tools to be used by investment advisers, asset owners, fund managers, investment banks, stock exchanges and brokers when creating or assessing sustainable investment products. For the inclusion in the FTSE4Good Index Series, companies are required to implement corporate responsibility measures in a number of areas, including working towards environmental sustainability, mitigating and adapting to climate change, countering bribery and corruption, up-holding and supporting universal human rights, labor rights and ensuring good supply chain labor standards, and comply with strict global guidelines.

About Fosun

Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of one billion families in health, happiness and wealth. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK). As of 30 June 2023, Fosun International's total assets amounted to RMB834.9 billion; it received an AA MSCI ESG rating and was the only conglomerate in Greater China with such rating.